Punt C J, Kamm Y L, Wagener D J
Department of Medical Oncology, University Hospital Nijmegen, The Netherlands.
Anticancer Drugs. 1997 Jun;8(5):454-8. doi: 10.1097/00001813-199706000-00006.
In this phase IB study, 24 patients with advanced colorectal cancer were treated with escalating doses of weekly chronomodulated 48 h infusions of 5-fluorouracil (5-FU) biochemically modulated by methotrexate 40 mg/m2 and (6S)-leucovorin 8 x 45 mg orally. Two daily peak delivery periods (PDP), during which 65% of the daily dose was administered, were investigated: from 18.00 to 0.30 h and from 0.00 to 06.30 h. The maximal tolerated dose of 5-FU was 2800 mg/m2/48 h, with a PDP from 18.00 to 0.30 h.
在这项1B期研究中，24例晚期结直肠癌患者接受了每周递增剂量的5-氟尿嘧啶（5-FU）48小时持续静脉滴注治疗，5-FU由40mg/m²甲氨蝶呤和口服8×45mg（6S）-亚叶酸钙进行生化调节。研究了两个每日剂量高峰给药时段（PDP），即每日剂量的65%在这两个时段给药：18:00至0:30以及0:00至06:30。5-FU的最大耐受剂量为2800mg/m²/48小时，PDP为18:00至0:30。
